Liver (Steatohepatosis)

Molecular mechanisms and therapeutic targets in steatosis and steatohepatitis.
[18922966] Pharmacol Rev 60(3): 311-57 (2008)

Causes and metabolic consequences of Fatty liver.
[18723451] Endocr Rev 29(7): 939-60 (2008)

Pathology of nonalcoholic fatty liver disease.
[17951208] Am J Clin Pathol 128(5): 837-47 (2007)

Approach to the pathogenesis and treatment of nonalcoholic steatohepatitis.
[15277442] Diabetes Care 27(8): 2057-66 (2004)

The role of the lipogenic pathway in the development of hepatic steatosis.
[19195625] Diabetes Metab 34(6 Pt 2): 643-8 (2008)

Definition and natural history of metabolic steatosis: histology and cellular aspects.
[19195624] Diabetes Metab 34(6 Pt 2): 638-42 (2008)

The ins and outs of mitochondrial dysfunction in NASH.
[15223984] Diabetes Metab 30(2): 121-38 (2004)

Commonly used animal models of non-alcoholic steatohepatitis.
[19502161] Hepatobiliary Pancreat Dis Int 8(3): 233-40 (2009)

Advances in pediatric nonalcoholic fatty liver disease.
[19637286] Hepatology 50(4): 1282-93 (2009)

Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management.
[19065650] Hepatology 49(1): 306-17 (2009)

Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice.
[18317565] J Clin Invest 118(3): 829-38 (2008)

Common pathogenic mechanism in development progression of liver injury caused by non-alcoholic or alcoholic steatohepatitis.
[18198478] J Toxicol Sci 32(5): 453-68 (2007)

Nonalcoholic fatty liver disease: an overview of current insights in pathogenesis, diagnosis and treatment.
[18442193] World J Gastroenterol 14(16): 2474-86 (2008)

The blind men 'see' the elephant-the many faces of fatty liver disease.
[18240340] World J Gastroenterol 14(6): 831-44 (2008)

Insulin sensitizers in treatment of nonalcoholic fatty liver disease: Systematic review.
[17203528] World J Gastroenterol 12(48): 7826-31 (2006)

Treatment of nonalcoholic fatty liver disease.
[16610015] World J Gastroenterol 12(14): 2161-7 (2006)

Nonalcoholic fatty liver disease: from steatosis to cirrhosis.
[16447287] Hepatology 43(2 Suppl 1): S99-S112 (2006)

The histopathology of pediatric nonalcoholic fatty liver disease.
[16116643] Hepatology 42(3): 536-8 (2005)

Fatty liver: imaging patterns and pitfalls.
[17102041] Radiographics 26(6): 1637-53 (2006)

Role of cannabinoids in the development of fatty liver (steatosis).
[20204561] AAPS J 12(2): 233-7 (2010)

Nonalcoholic steatosis and steatohepatitis. V. Mitochondrial dysfunction in steatohepatitis.
[11804839] Am J Physiol Gastrointest Liver Physiol 282(2): G193-9 (2002)

Nonalcoholic steatosis and steatohepatitis IV. Nonalcoholic fatty liver disease abnormalities in macrophage function and cytokines.
[11751151] Am J Physiol Gastrointest Liver Physiol 282(1): G1-5 (2002)

Endocannabinoids and liver disease. IV. Endocannabinoid involvement in obesity and hepatic steatosis.
[18292184] Am J Physiol Gastrointest Liver Physiol 294(5): G1101-4 (2008)

Noninvasive imaging biomarkers for steatosis assessment.
[19877212] Liver Transpl 15(11): 1389-91 (2009)

Adiponectin, a key adipokine in obesity related liver diseases.
[21734787] World J Gastroenterol 17(23): 2801-11 (2011)

Betaine and nonalcoholic steatohepatitis: back to the future?
[21990946] World J Gastroenterol 17(32): 3663-4 (2011)

JNKs, insulin resistance and inflammation: A possible link between NAFLD and coronary artery disease.
[21987620] World J Gastroenterol 17(33): 3785-94 (2011)

Pathophysiology of insulin resistance and steatosis in patients with chronic viral hepatitis.
[22039318] World J Gastroenterol 17(36): 4055-62 (2011)

Roles of liver innate immune cells in nonalcoholic fatty liver disease.
[20872965] World J Gastroenterol 16(37): 4652-60 (2010)

Histopathology of nonalcoholic fatty liver disease.
[21072891] World J Gastroenterol 16(42): 5286-96 (2010)

Understanding mechanisms of the pathogenesis of nonalcoholic fatty liver disease.
[20458758] World J Gastroenterol 16(18): 2223-6 (2010)

Metabolic liver disease of obesity and role of adipose tissue in the pathogenesis of nonalcoholic fatty liver disease.
[17659704] World J Gastroenterol 13(26): 3540-53 (2007)

Novel findings for the development of drug therapy for various liver diseases: Liver microsomal triglyceride transfer protein activator may be a possible therapeutic agent in non-alcoholic steatohepatitis.
[21350309] J Pharmacol Sci 115(3): 270-3 (2011)

Molecular mediators of hepatic steatosis and liver injury.
[15254578] J Clin Invest 114(2): 147-52 (2004)

Insulin sensitisers in the treatment of non-alcoholic fatty liver disease: a systematic review.
[22059955] Health Technol Assess 15(38): 1-110 (2011)

Pathology of fatty liver disease.
[17486051] Mod Pathol 20 Suppl 1(-): S40-8 (2007)

Inflammatory mediators of hepatic steatosis.
[20300479] Mediators Inflamm 2010(-): 837419 (2010)

Non-alcoholic statohepatitis: physiopathological, clinical and therapeutic implications.
[15506907] Rev Esp Enferm Dig 96(9): 628-39; 440-8 (2004)

Fatty liver is associated with reduced SIRT3 activity and mitochondrial protein hyperacetylation.
[21044047] Biochem J 433(3): 505-14 (2011)

Hepatocyte-specific deletion of SIRT1 alters fatty acid metabolism and results in hepatic steatosis and inflammation.
[19356714] Cell Metab 9(4): 327-38 (2009)

Choline metabolism provides novel insights into nonalcoholic fatty liver disease and its progression.
[22134222] Curr Opin Gastroenterol 28(2): 159-65 (2012)

Hepatic microcirculation in fatty liver disease.
[18484615] Anat Rec (Hoboken) 291(6): 684-92 (2008)

Nonalcoholic steatohepatitis: a review of the literature and updates in management.
[20710138] South Med J 103(6): 547-50 (2010)

Pathogenesis of non-alcoholic fatty liver disease.
[19914930] QJM 103(2): 71-83 (2010)

Non-alcoholic fatty liver: a common manifestation of a metabolic disorder.
[14500857] QJM 96(10): 699-709 (2003)

Nonalcoholic steatohepatitis.
[15554595] Neth J Med 62(7): 217-24 (2004)

Nonalcoholic fatty liver disease: a manifestation of the metabolic syndrome.
[18939388] Cleve Clin J Med 75(10): 721-8 (2008)

Managing nonalcoholic fatty liver disease: recommendations for family physicians.
[17872748] Can Fam Physician 53(5): 857-63 (2007)

The genetics of nonalcoholic fatty liver disease.
[17519829] Ann Hepatol 6(2): 83-8 (2007)

Nonalcoholic fatty liver disease.
[15505593] Ann Hepatol 3(3): 93-9 (2004)

Adipokines in nonalcoholic steatohepatitis: from pathogenesis to implications in diagnosis and therapy.
[19753129] Mediators Inflamm 2009(-): 831670 (2009)

GI epidemiology: nonalcoholic fatty liver disease.
[17402991] Aliment Pharmacol Ther 25(8): 883-9 (2007)

Review article: Drug therapy for non-alcoholic fatty liver disease.
[16393299] Aliment Pharmacol Ther 23(2): 207-15 (2006)

Review article: the treatment of non-alcoholic steatohepatitis with thiazolidinediones.
[16268963] Aliment Pharmacol Ther 22(10): 897-905 (2005)

Review article: Non-alcoholic fatty liver disease.
[12694079] Aliment Pharmacol Ther 17(8): 977-86 (2003)

Review article: omega-3 fatty acids - a promising novel therapy for non-alcoholic fatty liver disease.
[20415840] Aliment Pharmacol Ther 31(7): 679-92 (2010)

Review article: diagnosis and treatment of non-alcoholic fatty liver disease.
[18532991] Aliment Pharmacol Ther 28(5): 503-22 (2008)

Review article: current management of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.
[18410557] Aliment Pharmacol Ther 28(1): 2-12 (2008)

Review article: epidemiology, pathogenesis and potential treatments of paediatric non-alcoholic fatty liver disease.
[18397387] Aliment Pharmacol Ther 28(1): 13-24 (2008)

Review article: Non-alcoholic fatty liver disease in morbidly obese patients and the effect of bariatric surgery.
[18081662] Aliment Pharmacol Ther 26 Suppl 2(-): 195-201 (2007)

Treatment of non-alcoholic fatty liver disease.
[16679470] Postgrad Med J 82(967): 315-22 (2006)

Nonalcoholic fatty liver disease.
[18356447] AJR Am J Roentgenol 190(4): 993-1002 (2008)

Nonalcoholic fatty liver disease.
[15795412] CMAJ 172(7): 899-905 (2005)

Systematic review: the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.
[21198708] Aliment Pharmacol Ther 33(5): 525-40 (2011)

Nonalcoholic fatty liver disease.
[19074370] J Lipid Res 50 Suppl(-): S412-6 (2009)

A growing burden: the pathogenesis, investigation and management of non-alcoholic fatty liver disease.
[17483247] J Clin Pathol 60(12): 1384-91 (2007)

TRPV1 activation prevents nonalcoholic fatty liver through UCP2 upregulation in mice.
[22395410] Pflugers Arch 463(5): 727-32 (2012)

Innate immunity and steatohepatitis: a critical role of another toll (TLR-9).
[20639084] Gastroenterology 139(1): 27-30 (2010)

Silencing a killer among us: ethanol impairs immune surveillance of activated stellate cells by natural killer cells.
[18166364] Gastroenterology 134(1): 351-3 (2008)

The role of insulin-sensitizing agents in the treatment of nonalcoholic steatohepatitis.
[21765869] Therap Adv Gastroenterol 4(4): 249-63 (2011)

Glitazones for human nonalcoholic steatohepatitis.
[21922031] Therap Adv Gastroenterol 4(5): 325-34 (2011)

Progression of alcoholic and non-alcoholic steatohepatitis: common metabolic aspects of innate immune system and oxidative stress.
[21150132] Drug Metab Pharmacokinet 26(1): 30-46 (2011)

The metabolic syndrome and nonalcoholic fatty liver disease in children.
[19444112] Curr Opin Pediatr 21(4): 529-35 (2009)

Ultrastructural findings in human nonalcoholic steatohepatitis.
[21476907] Expert Rev Gastroenterol Hepatol 5(2): 141-5 (2011)

The use of ultrasound in clinical setting for children affected by NAFLD: is it safe and accurate?
[21810223] Ital J Pediatr 37(-): 36 (2011)

Nonalcoholic fatty liver disease in children.
[19155426] J Am Coll Nutr 27(6): 667-76 (2008)

Kupffer cells in non-alcoholic fatty liver disease: the emerging view.
[19447517] J Hepatol 51(1): 212-23 (2009)

Molecular mechanisms of lipotoxicity in nonalcoholic fatty liver disease.
[18956292] Semin Liver Dis 28(4): 360-9 (2008)

Biomarkers in nonalcoholic fatty liver disease: a new era in diagnosis and staging of disease in children.
[20808243] J Pediatr Gastroenterol Nutr 51(4): 378-9 (2010)

S-Adenosylmethionine in cell growth, apoptosis and liver cancer.
[18336669] J Gastroenterol Hepatol 23 Suppl 1(-): S73-7 (2008)

NASH: The Hepatic injury of Metabolic syndrome: a brief update.
[21475547] Int J Health Sci (Qassim) 3(2): 265-70 (2009)

Risk factors and mechanisms of non-alcoholic steatohepatitis.
[18667295] Pathophysiology 15(2): 109-14 (2008)

Signal transducer and activator of transcription 3 in liver diseases: a novel therapeutic target.
[21552420] Int J Biol Sci 7(5): 536-50 (2011)

The role of hepatic fat accumulation in pathogenesis of non-alcoholic fatty liver disease (NAFLD).
[20426802] Lipids Health Dis 9(-): 42 (2010)

Fatty acids and the endoplasmic reticulum in nonalcoholic fatty liver disease.
[21328622] Biofactors 37(1): 8-16 (2011)

An overview of nonalcoholic steatohepatitis: past, present and future directions.
[21188334] J Gastrointestin Liver Dis 19(4): 415-23 (2010)

Anti-IL-17 antibody improves hepatic steatosis by suppressing interleukin-17-related fatty acid synthesis and metabolism.
[24396389] Clin Dev Immunol 2013():253046 (2013)

KASL clinical practice guidelines: management of nonalcoholic fatty liver disease.
[24459637] Clin Mol Hepatol 19(4):325-48 (2013)

Prevention of nonalcoholic steatohepatitis in rats by two manganese-salen complexes.
[24375162] Iran Biomed J 18(1):41-8 (2014)

Caveolin-1 provides palliation for adverse hepatic reactions in hypercholesterolemic rabbits.
[24475013] PLoS One 9(1):e71862 (2014)

Eriocitrin ameliorates diet-induced hepatic steatosis with activation of mitochondrial biogenesis.
[24424211] Sci Rep 4():3708 (2014)

Role of docosahexaenoic acid treatment in improving liver histology in pediatric nonalcoholic fatty liver disease.
[24505350] PLoS One 9(2):e88005 (2014)

Clinical approaches to non-alcoholic fatty liver disease.
[24587650] World J Gastroenterol 20(7):1712-23 (2014)

5-cholesten-3beta,25-diol 3-sulfate decreases lipid accumulation in diet-induced nonalcoholic fatty liver disease mouse model.
[23258548] Mol Pharmacol 83(3):648-58 (2013)

Diagnosis and management of non-alcoholic fatty liver disease and related metabolic disorders: consensus statement from the Study Group of Liver and Metabolism, Chinese Society of Endocrinology.
[23560695] J Diabetes 5(4):406-15 (2013)

Metformin in non-alcoholic fatty liver disease: A systematic review and meta-analysis.
[24648894] Biomed Rep 1(1):57-64 (2013)

Non-Alcoholic Fatty Liver Disease: Current Perspectives and Future Direction in Disease pathogenesis, Treatment and Diagnosis.
[24660114] Med Chem (Los Angeles) 2(): (2012)

Fatty liver in childhood.
[24653792] World J Hepatol 6(1):33-40 (2014)

A randomized trial of iron depletion in patients with nonalcoholic fatty liver disease and hyperferritinemia.
[24659891] World J Gastroenterol 20(11):3002-10 (2014)

Rapid development of non-alcoholic steatohepatitis in Psammomys obesus (Israeli sand rat).
[24651520] PLoS One 9(3):e92656 (2014)

Comments to Prediction of Advanced Fibrosis in Nonalcoholic Fatty Liver Disease: An Enhanced Model of BARD Score.
[24672667] Gut Liver 8(2):228 (2014)

Noninvasive Diagnosis of NASH and Liver Fibrosis Within the Spectrum of NAFLD.
[24683373] Gastroenterol Hepatol (N Y) 8(10):661-8 (2012)

Thyroid hormone analogues and derivatives: Actions in fatty liver.
[24672641] World J Hepatol 6(3):114-29 (2014)

Pathophysiology of NASH: perspectives for a targeted treatment.
[23394092] Curr Pharm Des 19(29):5250-69 (2013)

Genetic signatures in choline and 1-carbon metabolism are associated with the severity of hepatic steatosis.
[23292069] FASEB J 27(4):1674-89 (2013)

Therapies for nonalcoholic steatohepatitis.
[24707234] Gastroenterol Hepatol (N Y) 9(1):40-2 (2013)

Predictors of nonalcoholic steatohepatitis in obese children.
[22129796] Gastroenterol Nurs 34(6):434-7 (2011)

Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States.
[23175136] Hepatology 57(4):1357-65 (2013)

The effect and mechanism of tamoxifen-induced hepatocyte steatosis in vitro.
[24603540] Int J Mol Sci 15(3):4019-30 (2014)

Leptin is key to peroxynitrite-mediated oxidative stress and Kupffer cell activation in experimental non-alcoholic steatohepatitis.
[23207144] J Hepatol 58(4):778-84 (2013)

Pediatric non-alcoholic steatohepatitis: the first report on the ultrastructure of hepatocyte mitochondria.
[24764670] World J Gastroenterol 20(15):4335-40 (2014)

Downloaded from http://www.kidney.de - The Database of Free Medical Reviews - The Metatextbook of Medicine - Ossip Groth

All Medline data shown were primarily retrieved from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Fatal error: Uncaught Error: Call to undefined function mysql_connect() in C:\Inetpub\vhosts\kidney.de\httpdocs\bdom\Liver (Steatohepatosis).php:92 Stack trace: #0 {main} thrown in C:\Inetpub\vhosts\kidney.de\httpdocs\bdom\Liver (Steatohepatosis).php on line 92